Mayo Clinic Comprehensive Cancer Center Support Grant

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Abstract

Mayo Clinic Comprehensive Cancer Center (MCCCC) is the only National Cancer Institute (NCI) Designated Comprehensive Cancer Center in the United States with three NCI Comprehensive Cancer Center sites, operating within the Mayo Clinic campuses in Rochester, MN; Jacksonville, FL; and Phoenix/Scottsdale, AZ. Our goals are to: provide exceptional, unparalleled cancer diagnosis, prevention, and treatment to patients within our regional catchment areas and from across the nation; conduct innovative transdisciplinary research to discover more effective means to prevent, treat, and cure cancer in its earliest and advanced stages; share our data, platforms, and knowledge to drive research and transform cancer care and clinical trials; engage patients and communities to assure optimal cancer outcomes for all; and educate, train, and mentor the cancer workforce of the future. Over the last four years, MCCCC underwent a full transformation with a new Executive Director, Senior Leadership Team, and Research Program and Disease Group leaders. Community Outreach & Engagement and Cancer Research Training & Education were rebuilt with new leaders and impactful programs. Membership was enhanced with 363 Full Members (46% new; 116 newly recruited) and >200 Associate and Trainee Members. Building upon innovative institutional strengths and scientific opportunities, the Center’s Research Programs were reorganized into six scientific discipline, platform-based programs: Cancer Prevention, Control & Survivorship; Risk Assessment, Early Detection & Interception; Cancer Genomics, Signaling & Metastasis; Cancer Immunology & Immunotherapeutics; Novel Therapeutics & Therapeutic Modalities; and Advanced Clinical Trials & Translational Sciences. As a result, in this 5-year period, MCCCC achieved the highest performance metrics in its 50-year history. Research funding increased 30% to $150M in annual direct costs, peer-reviewed cancer funding 26% to $74.2M, and NCI funding 8% to $46M, with 5 NCI SPOREs and 83 multi-investigator, programmatic grants. Compared to the prior 5-years, publications increased 72% (7,997; 28% high impact). Interventional clinical trial accrual increased 24-fold (191,761) and interventional treatment trial accrual increased 34% (8,520); 38% of patients accrued to therapeutic trials were from rural regions of the U.S. while 11% were racial/ethnic minorities. MCCCC led or participated significantly in 164 practice-changing clinical trials, leading to 50 new cancer drug approvals. Guided by the MCCCC 2030 Strategic Plan, we will drive and deepen innovative discovery science; detect and intercept cancer in its earliest stages; discover novel therapeutics and therapeutic modalities; transform cancer research, clinical practice, and community health with data science and artificial intelligence; and transform and decentralize cancer care delivery and clinical trials beyond our walls to home and community settings. We will share our platforms, knowledge, and expertise to assure that cancer care is accessible to all - at any place and any time - transcending geographic and physical barriers to meet patient and community needs.